- AstraZeneca has acknowledged past challenges but is now stronger and more resilient.
- Grateful for shareholder support and the dedication of its talented team.
- AstraZeneca India is shaping the future of the healthcare industry.
- The "Science Can, We Can" mindset drives the company's success.
- Aiming to make a positive impact on patients' lives.
- Remarkable achievements in fiscal year 22-23.
- Product sales showed significant growth of 24%.
- Total comprehensive income grew impressively by 62%.
- Key groundbreaking molecules include Tagrisso, Lynparza, Imfinzi, Fasenra, and Calquence.
- Focus on oncology has yielded significant success.
- Indian pharmaceutical market is growing, with India as the 5th largest economy in 2023.
- India's GDP growth of 6.8% in 2022 demonstrates resilience.
- Initiatives like PM GatiShakti and Production-Linked Incentives will boost economic progress.
- Indian Pharmaceutical Market for FY 2022-23 is estimated at Rs. 200,506 crores ($24.1 billion).
- Indian companies hold an 82% share of the market by value.
- AstraZeneca India maintained excellent safety and quality performance.
- Achieved zero Lost Time Injury and zero stockouts.
- Actively working to achieve zero carbon emissions by 2025.
- Planted over 10.5 million trees worldwide through the AZ Forest program.
- Partnering with local communities to support sustainability.
- Prioritizing investments in focus areas and new therapies in FY 23-24.
- Introduced new indications and products, especially in Cardiovascular, Renal, Metabolics (CVRM), and Oncology.
- Cost optimization and controls are a focus area for management.
- Corporate Social Responsibility initiatives include the Ganga Godavari Screening Programme.
- The Young Health Programme empowers young individuals to make informed health choices.
- Actively investing in biodiversity and nature conservation.
- Pledged to fulfill the wishes of critically ill children in collaboration with the Make-A-Wish Foundation.
- Expresses gratitude to all stakeholders, including shareholders, employees, and healthcare communities.
- Pipeline includes more than 15 new assets and launches in the next three to four years.
- Oncology remains a strong focus, with several top-performing brands.
- Digital transformation and partnerships are key strategies for improving patient outcomes and access to healthcare.
- Anchoring partnerships with organizations like AstraZeneca Pharma India Limited and NASSCOM.
- Provided 10+ solutions and are upscaling programs for nurses.
- Reached 10 lakh+ patients with healthcare initiatives.
- Focusing on sustainability with programs like the Young Health Programme and cancer screening.
- Focusing on growth through innovation with new products and indications.
- Patient-centricity is central to their strategy.
- Aims to make a positive impact on society with initiatives like the Young Health Programme.
- CFO Rajesh Marwaha retiring, with Bhavana Agarwal assuming the role.
- Strong financial growth over the years.
- Zero-debt status.
- Investing in diabetes, cardiovascular, oncology, and respiratory areas.
- Top-selling brands include Tagrisso, Brilinta, and Lynparza.
- Focus on patient identification and access for products like Fasenra.
- Promising growth for Fasenra.
- Actively entering the rare disease sector with a dedicated business unit.
- Working closely with the government for rare disease initiatives.
- Koselugo is the first rare disease product launched in India.
- New launches like Tezspire and [BrestTri] are in the pipeline.
- NLEM additions have not had a significant impact on the company.
- On a growth trajectory with a focus on new launches.
- Working to improve patient access to critical therapies.
- Optimistic about becoming a market leader in oncology.
- Introducing Enhertu, an important treatment, in India.
- Strategically positioned for further growth.
- The impact of NLEM is not substantial for the company.
- Import-dependent, leading to foreign exchange outflows.
- Cash flow primarily allocated to market-shaping activities and product launches.
- Accelerated depreciation for some assets.